핵심 개념
Transapical valve replacement effectively treats mitral regurgitation.
초록
The content discusses the successful use of the Tendyne transcatheter mitral valve replacement (TMVR) for patients with severe symptomatic mitral regurgitation (MR) and severe mitral annular calcification (MAC). The procedure showed excellent procedural success, relief of MR, and improvements in cardiac hemodynamics and quality of life. The Tendyne TMVR device design, patient outcomes, and trial results are detailed, highlighting the positive impact on patients' health and quality of life.
Key Highlights:
- Tendyne TMVR insertion through the cardiac apex
- Excellent procedural success and relief of MR
- Improvements in hemodynamics, functional status, and quality of life
- Trial results from 70 centers with 100 roll-in patients
- Survival rates and effectiveness of the Tendyne valve
- Impact on cardiac function and quality of life
- Outcomes for patients with severe MAC
- Hemodynamic improvements and quality of life scores
- Challenges and considerations for the procedure
통계
"The survival was 74% at 12 months. The valve was very effective at eliminating much regurgitation, and 96.5% of patients had either zero or 1+ at a year, and 97% at 30 days had no mitral regurgitation."
"Cumulative adverse outcomes at 1 year were 27% all-cause mortality, 21.6% cardiovascular mortality, 5.4% all-cause stroke, 2.3% myocardial infarction (MI), 2.2% post-operative mitral reintervention, no major but 2.3% minor device thrombosis, and 32.4% major bleeding."
인용구
"For this new procedure, with new operators, there was no intraprocedural mortality, and procedural survival was 100%." - Jason Rogers, MD
"There was a consistent and steady improvement in KCCQ [Kansas City Cardiomyopathy Questionnaire] score, as expected, as patients recovered from this invasive procedure." - Jason Rogers, MD